41例霍奇金淋巴瘤综合治疗的疗效观察  

The Analysis for Results of the Treatment of Hodgkin′s Disease:41 Cases with Combined Chemoradiotherapy

作　　者：苏航[1] 达永[1] 陈喜林[1] 肖秀斌[1] 俞受程[1] 张伟京[1] 

机构地区：[1]解放军第307医院肿瘤二科,北京市100039

出　　处：《中国肿瘤临床》2005年第12期697-699,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:对霍奇金淋巴瘤(HL)患者综合治疗的方案、疗效、不良反应进行总结,为今后选择治疗策略提供借鉴和指导。方法:41例HL患者化疗后接受两种不同剂量及设野的放疗,并对疗效及不良反应进行随访。结果:采用ABVD、MOEP/ABV、COEP/BACOP、CHOP及MOPP化疗方案的单周期有效率分别为85.5%、75.7%、70.4%、69.8%、65.7%;接受受累野照射或扩大野照射的两组CR率分别为82.3%和83.3%;放疗后出现局部纤维化15例,心电图明显异常8例,心包、胸腔积液4例,第二癌1例。综合治疗5年总生存率(OS)91.2%,3年总生存率94.9%。结论:ABVD仍为HL的首选化疗方案;30Gy<DT≤40Gy剂量组与40Gy<DT≤55Gy剂量组间远期疗效无显著统计学差异,但低剂量组不良反应明显小于另一组。Objective: To explore an optimal method of promoting the curative effect and the quality of life through reviewing the responses, survival rate and side effect to chemoradiotherapy in 41 patients at our department, with Hodgkin's Lymphoma (HL), during 10 years. Methods: All patients with HL received multicycle chemotherapy and a followed-up radiation therapy with two different doses and fields. Results: The response rate of single cycle for the regime of ABVD, MOEP/ABV, COEP/BACOP, CHOP and MOPP was 85.5%, 75.6%, 70.4%, 69.8% and 65.7%, respectively. For the two groups of patients receiving the involved-field radiotherapy and the extended-field radiotherapy alone, the clinical complete response (CR) rate was 82.3% and 83.3% respectively. The radiotherpy-related local fibrosis occurred in 15 cases(36.6%) and abnormality on electrocardiogram was found in 8(19.5%); hydropericardium and pleural effusion occurred in 4 cases and the second malignancy was observed in one case. The 5-year overall survival (OS) rate was 91.2% and 3-year OS rate was 94.9%. Conclusions: The ABVD regime is still the first choice of chemotherapy for the patients with HL; there is no statistical difference for the long-term effect of the treatment between the group with the 30Gy<DT≤40Gy dosage and the 40Gy<DT≤55Gy dosage, but side effects of lower-dose group is significantly less than another.

关 键 词：霍奇金淋巴瘤 综合治疗 疗效 

分 类 号：R733.1[医药卫生—肿瘤]